BEAM
Price
$25.51
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
46 days until earnings call
GLUE
Price
$5.95
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
49 days until earnings call
Ad is loading...

BEAM vs GLUE

Header iconBEAM vs GLUE Comparison
Open Charts BEAM vs GLUEBanner chart's image
Beam Therapeutics
Price$25.51
Change-$0.00 (-0.00%)
Volume$787.69K
CapitalizationN/A
Monte Rosa Therapeutics
Price$5.95
Change-$0.00 (-0.00%)
Volume$141.6K
CapitalizationN/A
View a ticker or compare two or three
BEAM vs GLUE Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
BEAM vs. GLUE commentary
Sep 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and GLUE is a Hold.

COMPARISON
Comparison
Sep 20, 2024
Stock price -- (BEAM: $25.51 vs. GLUE: $5.95)
Brand notoriety: BEAM and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 83% vs. GLUE: 65%
Market capitalization -- BEAM: $2.1B vs. GLUE: $365.17M
BEAM [@Biotechnology] is valued at $2.1B. GLUE’s [@Biotechnology] market capitalization is $365.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $599.73B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileGLUE’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • GLUE’s FA Score: 0 green, 5 red.
According to our system of comparison, GLUE is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while GLUE’s TA Score has 6 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 5 bearish.
  • GLUE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +5.76% price change this week, while GLUE (@Biotechnology) price change was -4.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.38%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1.46%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 04, 2024.

GLUE is expected to report earnings on Nov 07, 2024.

Industries' Descriptions

@Biotechnology (+7.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.1B) has a higher market cap than GLUE($365M). GLUE YTD gains are higher at: 5.310 vs. BEAM (-6.282). GLUE has higher annual earnings (EBITDA): -131.78M vs. BEAM (-162.88M). BEAM has more cash in the bank: 1.01B vs. GLUE (262M). GLUE has less debt than BEAM: GLUE (44.4M) vs BEAM (165M). BEAM has higher revenues than GLUE: BEAM (353M) vs GLUE (5.76M).
BEAMGLUEBEAM / GLUE
Capitalization2.1B365M576%
EBITDA-162.88M-131.78M124%
Gain YTD-6.2825.310-118%
P/E RatioN/AN/A-
Revenue353M5.76M6,130%
Total Cash1.01B262M385%
Total Debt165M44.4M372%
TECHNICAL ANALYSIS
Technical Analysis
BEAMGLUE
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 2 days ago
88%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OFSFX22.690.09
+0.40%
Olstein Strategic Opportunities Adviser
LGASX65.810.03
+0.05%
ClearBridge Small Cap FI
FSMAX85.690.03
+0.04%
Fidelity Extended Market Index
BARDX10.43-0.03
-0.29%
iShares Developed Real Estate Idx Inv A
PIVYX43.30-0.15
-0.35%
Putnam International Capital Opp Y

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with RXRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
+0.51%
RXRX - GLUE
49%
Loosely correlated
+2.07%
MDGL - GLUE
47%
Loosely correlated
-0.01%
NRIX - GLUE
44%
Loosely correlated
-0.36%
MGTX - GLUE
42%
Loosely correlated
+0.47%
BEAM - GLUE
42%
Loosely correlated
-0.27%
More